RAD Increases Ownership in Radiopharm Ventures to 87.5%
MWN-AI** Summary
Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX) has increased its ownership in Radiopharm Ventures, LLC, from 75% to 87.5%. This joint venture with the prestigious MD Anderson Cancer Center aims to advance innovative cancer treatment solutions. Since its inception in September 2022, Radiopharm Ventures has made notable strides, particularly with its lead candidate, Betabart (RV01), a monoclonal antibody targeting the immune checkpoint protein B7H3. This protein is often overexpressed in cancer cells, making it a critical target for therapeutic intervention. Betabart recently received Investigational New Drug (IND) clearance from the U.S. FDA for a Phase I trial, with the first patient expected to be dosed in Q1 2026, marking a significant milestone as it represents the first clinical trial globally aimed at B7H3 using a systematic radiopharmaceutical approach.
Riccardo Canevari, CEO of Radiopharm, expressed enthusiasm for increasing the company’s stake in the venture, highlighting the exciting progress being made in the cancer therapeutic pipeline. In addition to Betabart, two other preclinical assets have shown promising early results and are on track for final candidate selection in 2026, showcasing the potential to treat multiple types of solid tumor cancers.
This strategic move not only strengthens Radiopharm's position within the joint venture but also reflects its commitment to addressing high unmet medical needs in oncology. With a robust clinical pipeline that includes various Phase trials targeting solid tumors, Radiopharm is poised to make significant contributions to the development of advanced cancer therapies, underpinned by the strong partnership with MD Anderson's expertise in molecular imaging and antigen discovery.
MWN-AI** Analysis
Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX) has recently increased its ownership stake in Radiopharm Ventures, LLC, from 75% to 87.5%. This strategic move comes as the joint venture, formed with the prestigious MD Anderson Cancer Center in 2022, demonstrates exciting advancements in its cancer therapeutic pipeline, especially with its lead candidate, Betabart. Betabart targets B7H3, a protein closely associated with various solid tumors and has obtained FDA IND clearance for a Phase I trial expected to begin dosing its first patient in Q1 2026.
Investors should note the significance of this development in light of the emerging landscape of radiopharmaceuticals, particularly targeting B7H3, which is over-expressed in a majority of solid tumors but rarely found in healthy tissue. The global race to bring novel cancer treatments to market, particularly those focused on immunotherapy and radiopharmaceuticals, positions Radiopharm in a potentially lucrative sector.
The increase in ownership reflects Radiopharm's confidence in the clinical potential of their products, particularly Betabart, as it prepares for first-in-human trials. Alongside this, two additional preclinical assets are showing early promise and could transition into final candidate selection in the coming years.
For investors, Radiopharm's continued ownership expansion signifies a commitment to its pipeline, which comprises other innovative therapeutic approaches, suggesting potential for sustained growth. With the company's active engagement in high unmet medical needs in oncology, RAD may offer an attractive opportunity as it advances its clinical programs.
The stock’s performance may inherently reflect these developments; thus, keeping an eye on clinical milestones, partnership announcements, and FDA interactions will be crucial for evaluating future investment in Radiopharm.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm Theranostics
- Leading candidate Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance for a Phase I therapeutic trial in multiple solid tumors expected to dose the first patient in Q1 2026
- First clinical trial globally targeting B7H3 with a systemic radiopharmaceutical
- Two additional preclinical Radiopharm Ventures’ assets show early positive results with plans to move to final candidate selection in 2026
SYDNEY, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical needs, is pleased to announce that it has increased its ownership stake in Radiopharm Ventures, LLC, a joint venture created with The University of Texas MD Anderson Cancer Center (MDACC), from 75% to 87.5%.
Radiopharm’s decision to increase the ownership percentage comes as the joint venture continues to show promising progress in its cancer therapeutic pipeline, including the advancement of its leading B7H3 candidate and other preclinical assets.
B7H3 is an immune checkpoint protein that is very infrequently seen in healthy cells but is consistently overexpressed in the majority of cancer tissues. High expression of B7H3 in cancer is associated with greater tumor size and lymphatic invasion.
Riccardo Canevari, CEO & Managing Director of Radiopharm, commented: "We are very encouraged by the progress to date within Radiopharm Ventures. Now is an exciting time to increase our ownership in the joint venture, as we will soon have first-in-human results of Betabart (RV01) from our dose escalating therapeutic Phase I study. We remain confident in the potential value of this program and its potential to benefit patients battling a multitude of solid tumor cancers.”
The lead candidate monoclonal antibody (mAb) radiolabelled with 177Lu, Betabart, targets B7H3 and successfully received Investigational New Drug clearance in July 2025 by the U.S. Food and Drug Administration. The first patient in this Phase 1 therapeutic trial is expected to be dosed in Q1 2026, with a number of centers already activated.
Additionally, two other preclinical candidates have demonstrated early positive results and have progressed towards final candidate selection, with potential applications across multiple solid tumor types.
Radiopharm and MDACC launched Radiopharm Ventures, LLC in September 2022 to develop novel radiopharmaceutical products for cancer treatment. The joint venture leverages MD Anderson’s expertise in antigen discovery and molecular imaging alongside Radiopharm’s capabilities in developing targeted radiopharmaceutical therapies.
About Radiopharm Theranostics
Radiopharm Theranostics is a clinical-stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and four Phase 1 trials in a variety of solid tumor cancers, including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.
Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.
For more information:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com
Anne Marie Fields
Precision AQ (Formerly Stern IR)
E: annemarie.fields@precisionaq.com
Paul Hopper
Executive Chairman
P: +61 406 671 515
E: paulhopper@lifescienceportfolio.com
Media
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au
Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
Twitter – https://twitter.com/TeamRadiopharm
Linked In – https://www.linkedin.com/company/radiopharm-theranostics/
InvestorHub – https://investorhub.radiopharmtheranostics.com/
FAQ**
What impact does Radiopharm Theranostics Limited RADX anticipate from the first-in-human results of Betabart in its Phase I study on the future value and growth of Radiopharm Ventures, LLC?
How does Radiopharm Theranostics Limited RADX plan to leverage the expertise of MD Anderson in advancing the B7H3-targeting strategies developed within Radiopharm Ventures?
What are the expected timelines for the additional preclinical assets under Radiopharm Ventures, LLC, and how might these influence Radiopharm Theranostics Limited RADX's overall valuation and market strategy?
Can you elaborate on the strategic reasons behind Radiopharm Theranostics Limited RADX's decision to increase its ownership stake in Radiopharm Ventures, LLC, and what this means for future collaborations with MD Anderson?
**MWN-AI FAQ is based on asking OpenAI questions about Radiopharm Theranostics Limited (NASDAQ: RADX).
NASDAQ: RADX
RADX Trading
4.14% G/L:
$4.9156 Last:
43,102 Volume:
$4.64 Open:
